Van Herk Ventures
VC Fund
Rotterdam, The Netherlands
Van Herk Ventures is a VC fund in Rotterdam focused on Biotechnology and Health Care. Van Herk Ventures invests in the life sciences sector through direct investments in private and listed companies and in venture capital funds. For listed companies we can focus globally and for the private companies and venture capital funds we focus on the Benelux.Van Herk Investments invests in both listed and unlisted companies. The investmentfocus is on the construction, project development, biotechnology, financial services and energy sectors. For listed investments we look at shares all over the world from small to very large companies. For investments in non-listed companies we concentrate on the Benelux and we usually participate in companies with an enterprise value between € 10 and € 150 million at the time of the first participation.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Van Herk Ventures invests in
Stages Van Herk Ventures invests in
Countries Van Herk Ventures invests in
Investment Focus
Industry
- Biotechnology 5 (42%)
- Health Care 4 (33%)
- Life Science 3 (25%)
- Chemical 2 (17%)
- Therapeutics 2 (17%)
Stage
- Funding Round 3 (25%)
- Seed 2 (17%)
- Series A 2 (17%)
- Series B 1 (8%)
- Venture - Series Unknown 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Pan Cancer T
|
Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors. | $5.8M / Seed / Dec 08, 2025 | |
|
Pan Cancer T
|
Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors. | $4.6M / Seed / Jul 11, 2024 | |
SkylineDx
|
SkylineDx is an emerging commercial-stage company focused on the development and commercialization of innovative gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. These tests are designed to accurately determine the type or status of the disease or topredict a patient’s response to a specific treatment. | Venture - Series Unknown / Dec 21, 2021 | |
Sensara
|
Sensara empowers senior citizens and vulnerable people to enjoy their independence in a safe and healthier manner. Sensara alerts, signals and advices family and/or caregivers when needed. How? Our self-learning algorithms monitor 30 medically verified profiles against the information received from our sensors. The information is send to ouruser-friendly apps and interfaces. We believe that by knowing better what is going on, we can take care in better way. Off course, every client is always in control of their own data and privacy.Our modular product line offers solutions integrated seamlessly from your own home, independent and assisted living, until nursing home. Knowing your history can improve your care in the future. | $5.2M / Series A / Dec 11, 2019 | |
|
SkylineDx
|
SkylineDx is an emerging commercial-stage company focused on the development and commercialization of innovative gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. These tests are designed to accurately determine the type or status of the disease or topredict a patient’s response to a specific treatment. | $21.9M / Sep 02, 2019 | |
Ceradis
|
Ceradis develops and markets innovative environmental friendly solutions for plant nutrition, crop protection and formulation technology. Ceradis products have a patented formulation, optimal activity of the ingredients and excellent handling characteristics for the end-users. | $9.9M / Apr 15, 2019 | |
|
Sensara
|
Sensara empowers senior citizens and vulnerable people to enjoy their independence in a safe and healthier manner. Sensara alerts, signals and advices family and/or caregivers when needed. How? Our self-learning algorithms monitor 30 medically verified profiles against the information received from our sensors. The information is send to ouruser-friendly apps and interfaces. We believe that by knowing better what is going on, we can take care in better way. Off course, every client is always in control of their own data and privacy.Our modular product line offers solutions integrated seamlessly from your own home, independent and assisted living, until nursing home. Knowing your history can improve your care in the future. | $4.2M / Series A / Apr 20, 2017 | |
Nightbalance
|
NightBalance B.V. is an enterprise which was started by TU Delft alumni. In 2007 the research into improved position therapy aids began at the Delft University of Technology. NightBalance was founded in 2009 based on the research at the university in order to further develop the Sleep Position Trainer. | Series B / Jul 05, 2016 | |
Isobionics
|
Isobionics is a company that uses a proprietary biotechnology process for the production of flavor and fragrance ingredients. Its focus is on isoprenoid-based products for food, beverage, flavor and fragrance markets. The biotechnology process delivers products with higher quality and purity, at lower production cost. | Mar 24, 2014 | |
|
SkylineDx
|
SkylineDx is an emerging commercial-stage company focused on the development and commercialization of innovative gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. These tests are designed to accurately determine the type or status of the disease or topredict a patient’s response to a specific treatment. | Jan 01, 2014 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Van Herk Ventures invest in?
Van Herk Ventures invests primarily in Biotechnology, Health Care and Life Science startups, most often at Funding Round and Seed stage. Most of the 12 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Van Herk Ventures last invest?
The most recent investment recorded for Van Herk Ventures closed in Dec 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
